The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2015
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 28 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Feb 2014 Planned End Date changed from 1 Jan 2015 to 1 Oct 2015 according to ClinicalTrials.gov.
- 03 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov.